Next Article in Journal
Tetrandrine, a Compound Common in Chinese Traditional Medicine, Preferentially Kills Breast Cancer Tumor Initiating Cells (TICs) In Vitro
Next Article in Special Issue
Different Aspects of Self-Reported Quality of Life in 450 German Melanoma Survivors
Previous Article in Journal / Special Issue
Targeted Therapy for Biliary Tract Cancer
Cancers 2011, 3(2), 2255-2273; doi:10.3390/cancers3022255

Targeted Therapy in Nonmelanoma Skin Cancers

Department of Dermatology, University of Rome “Tor Vergata”, Via Montpellier 1, 00199, Rome, Italy
* Author to whom correspondence should be addressed.
Received: 11 March 2011 / Revised: 11 April 2011 / Accepted: 26 April 2011 / Published: 3 May 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
View Full-Text   |   Download PDF [260 KB, uploaded 3 May 2011]   |   Browse Figure


Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in light-skinned populations, and includes mainly Basal Cell Carcinomas (BCC), representing around 75% of NMSC and Squamous Cell Carcinomas (SCC). The incidence of these tumors is continuously growing. It was found that the overall number of procedures for NMSC in US rose by 76%, from 1,158,298 in 1992 to 2,048,517 in 2006. Although mortality from NMSC tends to be very low, clearly the morbidity related to these skin cancers is very high. Treatment options for NMSC include both surgical and nonsurgical interventions. Surgery was considered the gold standard therapy, however, advancements in the knowledge of pathogenic mechanisms of NMSCs led to the identification of key targets for drug intervention and to the consequent development of several targeted therapies. These represent the future in treatment of these common forms of cancer ensuring a high cure rate, preservation of the maximal amount of normal surrounding tissue and optimal cosmetic outcome. Here, we will review recent advancements in NMSC targeted therapies focusing on BCC and SCC.
Keywords: basal cell carcinoma (BCC); squamous cell carcinoma (SCC); EGFR; SMO inhibitor; COX2 basal cell carcinoma (BCC); squamous cell carcinoma (SCC); EGFR; SMO inhibitor; COX2
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Spallone, G.; Botti, E.; Costanzo, A. Targeted Therapy in Nonmelanoma Skin Cancers. Cancers 2011, 3, 2255-2273.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert